Skip to content

Study · Measured the body's own peptide · 1991

4 results

High vasoactive intestinal polypeptide plasma levels in patients with Barrett's esophagus.

Rossiter A, Guelrud M, Souney PF, Mendoza S, Rossiter G, Gelrud D

Scandinavian journal of gastroenterology1 May 1991Cited by 5 (Europe PMC)

PMID1871550 (opens in a new tab)DOI10.3109/00365529108998582 (opens in a new tab)PepBankPUB-01871550
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    Plasma VIP in healthy volunteers (20.6 pg/ml) was lower than in patients with Barrett's esophagus and severe reflux.

    In plain wordsHealthy volunteers had lower blood levels of the body's own VIP than patients with Barrett's esophagus and severe reflux.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePlasma VIP in severe reflux versus healthy volunteers
    Study

    n = 25

    Comparator
    Healthy volunteers
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Measurements

    plasma VIP
    20.6 pg/ml
    healthy volunteers

    Source sentences

    Summary
    The mean VIP plasma concentration in 11 healthy volunteers (20.6 +/- 0.65 pg/ml) was significantly lower than the mean value observed in the subgroup of patients with severe gastroesophageal reflux (p less than 0.01).
    1 context sentence
    Summary · context
    We have evaluated the correlation between vasoactive intestinal polypeptide (VIP) plasma concentration and severity of gastroesophageal reflux in patients with Barrett's esophagus and the possible differences in the VIP values of these patients compared with healthy volunteers.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In patients with Barrett's esophagus, plasma VIP was higher in severe gastroesophageal reflux (25.6 pg/ml) than in moderate reflux (18.9 pg/ml).

    In plain wordsIn patients with Barrett's esophagus, the body's own VIP in blood was higher in severe reflux than in moderate reflux.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePlasma VIP in severe versus moderate reflux
    Study

    n = 24

    Comparator
    Patients with moderate reflux
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Measurements

    plasma VIP
    25.6 pg/ml
    severe reflux
    plasma VIP
    18.9 pg/ml
    moderate reflux

    Source sentences

    Summary
    The mean VIP plasma concentration in 14 patients with severe gastroesophageal reflux was 25.6 +/- 0.75 pg/ml, significantly higher than the mean value observed in 10 patients with moderate reflux (18.9 +/- 0.67 pg/ml) (p less than 0.01).
    1 context sentence
    Summary · context
    We have evaluated the correlation between vasoactive intestinal polypeptide (VIP) plasma concentration and severity of gastroesophageal reflux in patients with Barrett's esophagus and the possible differences in the VIP values of these patients compared with healthy volunteers.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In patients with Barrett's esophagus, plasma VIP correlated significantly with lower esophageal sphincter pressure (r = -0.9253), so higher VIP went with lower pressure.

    In plain wordsIn patients with Barrett's esophagus, higher blood levels of the body's own VIP were linked to lower sphincter pressure.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableCorrelation of plasma VIP with lower esophageal sphincter pressure
    Study

    n = 24

    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Measurements

    correlation coefficient r
    −0.9253
    VIP versus LES pressure

    Source sentences

    Summary
    There was a significant correlation between LES pressure and VIP plasma level (r = -0.9253; p less than 0.01).
    1 context sentence
    Summary · context
    We have evaluated the correlation between vasoactive intestinal polypeptide (VIP) plasma concentration and severity of gastroesophageal reflux in patients with Barrett's esophagus and the possible differences in the VIP values of these patients compared with healthy volunteers.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    Plasma VIP in patients with moderate reflux did not differ significantly from that in healthy volunteers.

    In plain wordsPatients with moderate reflux and healthy volunteers had similar blood levels of the body's own VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changePlasma VIP in moderate reflux versus healthy volunteers
    Study

    n = 21

    Comparator
    Healthy volunteers
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    VIP values in patients with moderate reflux were not significantly different from those observed in our volunteers.
    1 context sentence
    Summary · context
    We have evaluated the correlation between vasoactive intestinal polypeptide (VIP) plasma concentration and severity of gastroesophageal reflux in patients with Barrett's esophagus and the possible differences in the VIP values of these patients compared with healthy volunteers.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.